Evidence map›Paper›PMID 27206733›Full record

Observational studyTrials2016

Type-2 diabetes primary prevention program implemented in routine primary care: a process evaluation study.

Alvaro Sánchez, Carmen Silvestre, Natalia Campo, Gonzalo Grandes, PreDE research group

2 registry-linked trialsAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01365013 phase4completednot on this map

Effectiveness of the Translation of a Type 2 Diabetes Primary Prevention Program in Routine Context of Primary Heath Care

TypeinterventionalSponsorBasque Health ServiceRan2011 to 2015Enrolled1,113ConditionsPrediabetic StateArmsDE-PLAN, Control group
NCT01365026 naunknown statusnot on this map

Feasibility and Effectiveness of Innovative Programs for Health Promotion in Primary Care: The 'Prescribe Healthy Life' Project (PVS)

TypeinterventionalSponsorBasque Health ServiceRan2016 to 2018Enrolled4,017ConditionsHealth Promotion, Health Education, Patient Education, CounselingArmsPVS: Programa de Vida Saludable
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alvaro SánchezPrimary Care Research Unit of Bizkaia, Basque Health Service (Osakidetza), Bilbao, Spain. alvaro.sanchezperez@osakidetza.net.
Carmen SilvestreQuality Unit, Gipuzkoa Health Region, Osakidetza, Spain.
Natalia CampoTxagorritxu Hospital, Basque Health Service, Osakidetza, Spain.
Gonzalo GrandesPrimary Care Research Unit of Bizkaia, Basque Health Service (Osakidetza), Bilbao, Spain.
PreDE research group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProcess evaluation studies are recommended to improve our understanding of underlying mechanisms related to clinicians, patients, context and intervention delivery that may impact on trial or program results and on their potential transferability to practice. This paper aims to document the translation of a type-2 diabetes (T2D) prevention program into the routine context of several primary care centers, assessing process indicators related to clinician adoption, patient recruitment, exposure to the intervention components and baseline characteristics.

methodsAn observational descriptive process evaluation study was conducted of the 2.5-year implementation of the Prevention of Diabetes in Euskadi cluster randomized trial in 14 primary care centers of the Basque Health Service (Osakidetza). The clinical intervention consisted of three components: (1) risk screening, (2) an educational intervention promoting healthy lifestyles, and (3) remote support (follow-up). A passive dissemination strategy of providing training and materials was used to translate the intervention into practice. All non-diabetic patients aged 45 to 70 years who were identified as being at high risk of developing T2D were eligible for study inclusion. The RE-AIM framework guided the process evaluation.

resultsOverall, 31.4 % of family physicians and 57.6 % of nurses participated in the study, while 4170 out of 67,293 (6.2 %) targeted patients who attended the centers during the implementation period were reached through the screening. Around half of the screened patients were identified as being at high risk of developing T2D (FINDRISC score ≥14). The rate of refusal to participate and the proportion of women were higher in the intervention group. Finally, 634 and 454 non-diabetic 45- to 70-year-old patients who were at high risk of T2D were included in the control and intervention group centers (intervention reach = 48 %). Significant variability in most process indicators was observed at center level.

conclusionThe passive dissemination strategy has produced modest process indicators related to the adoption, reach and implementation of the intervention program, and reduced the possibility of its standardized application in heterogeneous contexts. The resulting different procedures and strategies used by the centers were associated with process outcomes. Context-specific variability and possible confounding will require rigorous procedures for analysis of the intervention effects.

trial registrationThe trial was registered in ClinicalTrials.gov (identifier: NCT01365013 ). Registered on June 2011.

Indexed as

Delivery of Health Care, IntegratedDiabetes Mellitus, Type 2Primary PreventionAgedCombined Modality TherapyFemaleHealth Knowledge, Attitudes, PracticeHealth PromotionHealthy LifestyleHumansMaleMass ScreeningMiddle AgedPatient Education as TopicProgram EvaluationRisk Assessment

Identifiers

PMID27206733
PMCPMC4875717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.